Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes

BACKGROUND: The therapeutic use of [(131)I]meta-iodobenzylguanidine ([(131)I]MIBG) is often accompanied by hematological toxicity, primarily consisting of severe and persistent thrombocytopenia. We hypothesize that this is caused by selective uptake of MIBG via the serotonin transporter (SERT) locat...

Descripción completa

Detalles Bibliográficos
Autores principales: Blom, Thomas, Meinsma, Rutger, di Summa, Franca, van den Akker, Emile, van Kuilenburg, André B. P., Hansen, Marten, Tytgat, Godelieve A. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382772/
https://www.ncbi.nlm.nih.gov/pubmed/34424429
http://dx.doi.org/10.1186/s13550-021-00823-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382772/
https://www.ncbi.nlm.nih.gov/pubmed/34424429
http://dx.doi.org/10.1186/s13550-021-00823-5

Ejemplares similares